Avelas Biosciences news

Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director

Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22

SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed to deliver a fluorescent marker

Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery

Observed re-excision rate was ~6% in patients whose surgeries included pegloprastide; current re-excision rates are estimated at 20-40% among all patients receiving an initial lumpectomy

Each year in the U.S., approximately 60,000 women undergo

SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company.

“Susan brings an exceptional background and skillset to the Avelas Board. She has had incredible success throughout her career and her knowledge and experiences will be very valuable in guiding Avelas towards a successful com

SAN DIEGO, December 4, 2018 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, presented the initial results of the first part of its Phase II clinical trial in a poster session at this week’s San Antonio Breast Cancer Symposium (SABCS). The poster, titled “Use of a fluorescent activatable cell penetrating peptide imaging agent (AVB-620) to identify positive and close margins intraoperatively